For an approach that takes full advantage of the integrated character of MImAbs’ antibody platform, R&D Partnership offers the possibility of outsourcing all or part of an R&D process, MImAbs acting as your remote laboratory in the early stage generation and development of a therapeutic antibody candidate. This approach includes:
- The establishment of a scientific work plan based on the team’s wealth of experience in immunotechnology (seven antibodies in clinical development)
- Generation, optimization, production, engineering (humanization, drug-coupling, etc.) of antibodies
- Validation using in vitro and in vivo immunopharmacology.
For each program, MImAbs allocates scientific operational resources and a project manager.
The Contracts are established on the basis of the number of FTEs involved in the program.
An FTE corresponds to a full-time highly skilled scientist and covers all the activities offered on the platform.